Tesamorelin

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH) primarily used to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. While effective for its approved indication, its clinical relevance is considered somewhat weaker compared to newer growth hormone-axis alternatives due to its short half-life and historical approval status.

Overview

Tesamorelin is a synthetic peptide that mimics the action of endogenous human growth hormone-releasing hormone (GHRH). It is specifically designed to have increased stability compared to native GHRH. Marketed under the brand name Egrifta WR, tesamorelin is an FDA-approved medication.

Approved Indications and Dosing

Tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. It is crucial to note that it is not indicated for general weight-loss management, and its long-term cardiovascular safety has not been established.

The FDA-labeled dosage for Egrifta WR is 1.28 mg injected subcutaneously once daily. There was an older formulation, Egrifta SV, which had a different recommended dosage (e.g., 2 mg SC once daily) and is not substitutable with Egrifta WR.

Mechanism of Action

As a GHRH analog, tesamorelin works by agonizing the GHRH receptor, thereby stimulating the pituitary gland to release growth hormone (GH). This action contributes to its effect on fat metabolism, particularly in reducing visceral adipose tissue associated with HIV-associated lipodystrophy. It operates within the GH-IGF-1 axis, specifically targeting GHRH receptor agonism, differentiating it from GH replacement (somatropin) or IGF-1 replacement (mecasermin).

Regulatory and Compounding Considerations

Tesamorelin is an established, FDA-approved drug product. For compounding pharmacies operating under Section 503A of the FDC Act, the bulk drug substance can be used if it is a component of an FDA-approved drug product and no applicable USP/NF monograph exists. However, because tesamorelin is commercially available as a branded product, any compounding analysis must carefully consider "essentially a copy" restrictions and other statutory conditions, including patient-specific prescriptions.

Current Status

Tesamorelin is considered an established but older peptide drug substance. While its efficacy for HIV-associated lipodystrophy is strong and well-documented by its FDA approval, its overall pharmacologic elegance and modern clinical relevance are viewed as somewhat weaker compared to newer agents in the growth hormone axis due to its short half-life. It remains a viable treatment option for its specific approved indication, but alternatives with potentially improved profiles are emerging in the broader therapeutic landscape.